Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 12 of 47

Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review (2 of 2)

A variety of validated assessment instruments are used to measure outcomes of treatment with atypical antipsychotics. Remission rates and changes in symptom severity are reported. Response rates are defined as the proportion of participants achieving an a priori-specified degree of improvement on a rating scale.

For personality disorders, either borderline (BPD) or schizotypal, several tools are used, including the Symptom Checklist 90 Revised (SCL-90-R), Clinical Global Impressions–BPD (CGI-BPD), the Hamilton Anxiety Rating Scale (HAM-A), and the Positive and Negative Symptoms Scale (PANSS). Post-traumatic stress disorder (PTSD) is assessed with the Clinician Administered PTSD Scale (CAPS). Substance abuse outcomes assessment tools include the Cocaine Craving Questionnaire (CCQ) and the Addiction Severity Index (ASI). Tourette’s syndrome evaluation includes the symptom-specific Yale Global Tic Severity (YGTS) scale and Clinical Global Impressions–Improvement (CGI-I) scale. For insomnia, sleep quality and time-to-onset are scored.